Skip to main content
| News

Polyphor discovers new class of antibiotics

24.10.2019

Researchers at the Allschwil pharmaceutical company Polyphor and the University of Zurich have discovered a novel antibiotics class. It has a unique mechanism of action that allows it to target multiple bacteria.

Research (Img: Alex011973/shutterstock)

The rapid emergence of antimicrobial resistance is a huge problem, particularly Gram-negative bacteria, according to a statement from the University of Zurich (UZH). Working with colleagues at Polyphor, UZH researchers have now discovered a new class of antibiotics that is effective against several Gram-negative microbes. In its own statement, Polyphor writes that the University of Basel, its Biozentrum and the Federal Institute of Technology in Zurich (ETH) were also involved in the research. The study was published in “Nature”.

The new class is known as Outer Membrane Protein Targeting Antibiotics (OMPTA). “The new antibiotics interact with essential outer membrane proteins in Gram-negative bacteria,” commented John Robinson from the UZH Department of Chemistry, who co-headed the study, in the UZH statement. The outer membrane of Gram-negative bacteria is important, because it protects the cells from toxic environmental factors such as antibiotics and is responsible for the uptake of nutrients. The antibiotics bind to complex fat-like substances “and to BamA, an essential protein of the outer membrane of Gram-negative bacteria”, explained Robinson. When the novel antibiotics bind to BamA, they destroy the membranes and the cells burst. Currently no clinical antibiotics target the outer membrane proteins, making the Polyphor and UZH finding particularly novel.

Polyphor is set to conduct in-human clinical trials on the new class of antibiotics. “POL7306, a first lead molecule of the OMPTA class, is now in preclinical development,” said Daniel Obrecht, chief scientific officer at Polyphor and co-head of the work. In the Polyphor statement he added: “We are proud to have discovered a novel class of antibiotics potentially addressing a major unmet medical need.” He also acknowledged the financial support of Innosuisse – the federal innovation agency, the Wellcome Trust, the Novo REPAIRImpact Fund and CARB-X.

CARB-X is one of the world’s biggest public-private partnerships conducting groundbreaking research to combat drug-resistant bacteria. Representing the Basel region, which is a leading center for antibiotics research, BaselArea.swiss is a member of CARB-X. The location promotion organization supports businesses eligible for CARB-X funding and consults the network regarding the support of companies.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Clinerion is now part of Citeline
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion is now part of Citeline

Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

BSI integrating AI from Parashift in banking software

Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest

UptownBasel joins IBM Quantum Network

UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
1 2 3 36

Do you have a question? We'd like to hear from you.